RxDoctor Payments Data

Caroline Morrison

Psychiatry · Naperville, ILNPI 1285707935

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,175 of the $43,781 with a category attached, or 75.8%. Alkermes, Inc. accounts for 82.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $18,027 and has fallen 57.7% since, to $7,632 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,781in general payments, 2019–2025

Across 180 payments — averaging $243.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$36K
  • AbbVie$6K
  • Lilly USA, LLC$271
  • Johnson & Johnson$177
  • Otsuka America Pharmaceutical, Inc.$172
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$141
  • plus $963 from 17 others

What the payments were for

  • Consulting fees$4,63011%
  • Speaking & faculty fees$33,17576%
  • Travel & lodging$2,5906%
  • Food & beverage$3,3328%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,781 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole16$23,272
MounjaroTirzepatide22$23,000
TrintellixVortioxetine Hydrobromide17$16,440
Lisdexamfetamine Dimesylate18$3,863
Bupropion XlBupropion Hcl184$3,353
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$2,410
Duloxetine Hcl124$1,897
Atomoxetine Hcl14$1,648
Fluoxetine Hcl53$1,166
Escitalopram Oxalate51$993
Methylphenidate ErMethylphenidate Hcl20$915
Venlafaxine Hcl ErVenlafaxine Hcl54$773
Buspirone Hcl32$772
Lamotrigine40$658
Sertraline Hcl62$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$271$23,52940 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$23,27216 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$70$16,44017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →